Barinthus Biotherapeutics

BRNS | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.74

-$0.02 (-2.50%)

Sep 8, 2026, 4:00 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $30.23M

Enterprise Value $-18.77M

Beta -0.36

Average Volume 69.36K

Shares Outstanding (Diluted) 40.85M

Shares Change YoY 1.25%

Institutional Ownership N/A

Exchange NASDAQ

ISIN US91864C1071

Price Performance

Price Change 1M 21.3%

Price Change 3M 6.0%

Price Change 6M 17.5%

Price Change YTD 0.7%

Price Change 1Y -29.5%

Price Change 3Y -56.0%

Price Change 5Y -95.4%

1M CAGR (ann.) 29.8%

1Y CAGR (ann.) -29.5%

5Y CAGR (ann.) -45.5%

All-Time CAGR -42.1%

Valuation

PE Ratio -0.72

Forward PE N/A

PEG Ratio -0.01

Forward PEG -0.04

PS Ratio N/A

Forward PS N/A

PB Ratio 0.53

P/FCF Ratio -1.14

P/Adj. FCF Ratio -1.09

P/OCF Ratio -1.14

EV/Sales N/A

EV/EBIT 0.45

EV/EBITDA 0.50

EV/FCF 0.71

Earnings Yield -139.2%

FCF Yield -87.4%

Adj. FCF Yield -91.6%

Financial Health

Net Cash $59.3M

Total Debt $10.3M

Cash & Short-Term Investments $59.3M

Total Assets $81.89M

Current Ratio 5.54

Quick Ratio 5.54

Debt / Equity Ratio 0.18

Debt / EBITDA -0.27

Debt / FCF -0.39

OCF / Debt -2.57

Interest Coverage -842.20

Altman Z-Score -5.68

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -4.8%

Returns

Return on Assets -51.0%

Return on Equity -59.2%

Return on Invested Capital -61.1%

Return on Capital Employed -63.3%

Return on Tangible Assets -60.6%

Historical Growth (CAGR)

Revenue CAGR 3Y 0.0%

Revenue CAGR 5Y -51.8%

Revenue CAGR 10Y N/A

EPS CAGR 3Y 21.1%

EPS CAGR 5Y -27.7%

EPS CAGR 10Y N/A

FCF CAGR 3Y 35.7%

FCF CAGR 5Y -1.7%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 4

EPS Growth Next 3Y N/A

Revenue Growth Next 3Y N/A

Earnings Date Nov 5, 2026

EPS Estimate (next Q) -$0.27

EPS Growth Est (next Q) -25.0%

Revenue Est (next Q) $216.9K

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $3

Price Target Upside 305.4%

Cash Flow

Operating Cash Flow $-26.43M

Free Cash Flow $-26.43M

Adj. Free Cash Flow $-27.7M

FCF Per Share -$0.65

OCF Per Share -$0.65

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-1.76M

Operating Income $-44.6M

EBITDA $-37.52M

Net Income $-41.74M

EPS (Diluted) -$1.03

Revenue / Employee N/A

Profit / Employee $-2.98M

Employees 14